a 3-part study to evaluate safety, tolerability, food effect and drug-drug interactions of rxc007 in healthy volunteers

Conditions: Fibrosis; Inflammation; Idiopathic Pulmonary Fibrosis; Non-alcoholic Steatohepatitis; Liver Diseases; Kidney Diseases

Summary: the purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (pk) and pharmacodynamics of rxc007.

the study will be split into 3 parts: part a, part b \& part c. the overall study will enrol up to 136 healthy males; maximum of 68 in part a, maximum of 44 in part b and maximum of 24 in part c. the purpose of part a is to evaluate the safety, tolerability and concentration of rxc007 in the blood when it is given as a single dose on one occasion at different dose strengths. in addition, one group in part a will investigate the effect of food on the safety, tolerability and concentration of rxc007 in the blood by taking a single dose of rxc007 following an overnight fast and then following a high fat breakfast. part a will consist of 6 planned groups of 6 participants: each group investigating a different dose strength starting at the lowest dose and gradually increasing in each group. if required and determined as necessary following dose escalation data review, part a may enrol up to a maximum of 4 additional cohorts with a maximum of 8 participants within each cohort. part a of the study will consist of a screening visit (between 28 and 2 days prior to first dose), a treatment period (consisting of a maximum of 5 days with 4 overnight stays) and a post-study follow-up visit on day 15. for the food effect cohort, an additional treatment period (consisting of a maximum of 5 days with 4 overnight stays) will be undertaken following an approximately 4-week washout period with a second follow-up visit to be conducted on day 15 following the second treatment period. the purpose of part b is to evaluate the safety, tolerability and concentration of rxc007 in the blood when it is given as a single dose once a day for a period of 14 days at different dose strengths. part b will consist of up to 2 planned groups of 6 participants; each group investigating a different dose strength based on the data generated during part a of the study. if required and determined as necessary following dose escalation data review, part b may enrol up to a maximum of 4 additional cohorts with a maximum of 8 participants within each cohort. part b of the study will consist of a screening visit (between 28 and 2 days prior to first dose), a treatment period (consisting of a maximum of 18 days with 17 overnight stays) and a post-study follow-up visit on day 28. within each cohort in part a and part b, 4 participants will receive rxc007 with the remaining 2 participants receiving a matching placebo. each cohort will follow a dose leader schedule, whereby 2 participants (1 active, 1 placebo) will be dosed a minimum of 24 hours prior to the remaining 4 participants in the cohort. between each cohort, safety and pk data up to the 72-hour post-last dose time point for part a and up to day 17 in part b will be evaluated by a dose escalation review committee (derc) to determine whether it is appropriate to dose escalate into the next cohort. if required, i.e., the safety or pharmacokinetics (pk) data indicates, dose modifications may be made in order to select an intermediate/lower dose. in addition, modifications may be made following both treatment periods for the food effect cohort in part a to dose all remaining cohorts in part a and part b in a fed state (with a standardised breakfast) and in part b, the dose regime may be modified in terms of frequency to increase dosing from once per day to multiple times per day. in addition, decisions may be made that the proposed length of the in-house treatment period in both part a \& part b should be reduced by one day (from day 4 to day 3 in part a and from day 17 to day 16 in part b). the purpose of part c is to evaluate the safety, tolerability and effect of rxc007 on the concentration of rosuvastatin and metformin in the blood to determine as to whether rxc007 affects the activity of the processes by which certain types of drugs are broken down (metabolised) in the body and therefore, whether rxc007 has the potential to interact with other drugs, affecting their desired effect in the body i.e., evaluating the drug-drug interaction potential of rxc007. part c will consist of 2 groups of 12 participants; group 1 evaluating the drug-drug interactions of rxc007 and rosuvastatin (at a dose strength of 10 mg in an oral tablet formulation) and group 2 evaluating the drug-drug interactions of rxc007 and metformin (at a dose strength of 500 mg in an oral tablet formulation). the dose strength of rxc007 to be evaluated will be selected based on review of the data generated in part b of the study. part c of the study will consist of a screening visit (between 28 and 2 days prior to first dose), a treatment period (consisting of either a maximum of 14 days with 13 overnight stays for group 1 or a maximum of 11 days with 10 overnight stays for group 2) and a post-study follow-up visit approximately 14 days following the last dose of rxc007 with rosuvastatin or metformin (either day 23 or day 21 respectively for group 1 and group 2).

Eligibility criteria:
inclusion criteria: 1. healthy male participants, between 18 and 55 years of age, inclusive. 2. male participant (and female partner of childbearing potential) willing to use a highly effective method of contraception or 2 effective methods of contraception, if applicable (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the participant) from first dose until 3 months after last dose of imp/nimp. 3. participant with a body mass index (bmi) of 18.0-32.0 kg/m2. 4. participant with a body weight of 60 kg or greater. 5. no clinically significant history of previous allergy / sensitivity to rxc007, rosuvastatin or metformin, or any of the excipients contained within the imp/nimp. 6. no clinically significant abnormal test results for serum biochemistry, haematology and/or urine analyses within 28 days before the first dose administration of the imp/nimp. 7. haemoglobin and haematocrit above the lower limit of the normal range for the reference laboratory. 8. alanine aminotransferase (alt) and aspartate aminotransferase (ast) \< 1.5 times the upper limit of the normal (uln) range for the reference laboratory. 9. participant with a negative urinary drugs of abuse (doa) screen (including alcohol) test results, determined within 28 days before the first dose administration of the imp/nimp (n.b.: a positive test result may be repeated at the investigator's discretion). 10. participant with negative human immunodeficiency virus (hiv), hepatitis b surface antigen (hbsag) and hepatitis c virus antibody (hcv ab) test results at screening. 11. no clinically significant abnormalities in 12-lead electrocardiogram (ecg) determined within 28 days before first dose of imp/nimp including a pr interval \> 220ms, qrs width \> 120ms and qtcf interval \> 450 ms. 12. no clinically significant abnormalities in vital signs (e.g., blood pressure (systolic blood pressure \> 140 mmhg) / heart rate, respiration rate, oral temperature) determined within 28 days before first dose of imp/nimp. 13. participant must be available to complete the study (including all follow-up visits). 14. participant must satisfy an investigator about his fitness to participate in the study. 15. participant must provide written informed consent to participate in the study. 16. participants with a negative covid-19 reverse transcription polymerase chain reaction (rt-pcr) test on admission (if required). exclusion criteria: 1. a clinically significant history of gastrointestinal disorder likely to influence imp/nimp absorption. 2. a clinically significant history of infection in the last 3 months. 3. use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements, antacids (part c cohort 1 only), any product known to be a substrate mainly metabolised by cyp enzymes within 28 days or 5 half-lives (whichever is longer) prior to the first dose of imp/nimp. 4. evidence of renal, hepatic, central nervous system, respiratory, cardiovascular or metabolic dysfunction. 5. participants who are unable to demonstrate the ability to swallow multiple "dummy" capsules (i.e., an empty gelatin capsules) of the size proposed for administration in a particular cohort/dose level (up to and including size 00). 6. participant with a glomerular filtration rate less than 80 ml/min/1.73m2 (calculated by cockcroft-gault equation. 7. a clinically significant history of drug or alcohol abuse (defined as the consumption of more than 14 units of alcohol a week) within the past two years. 8. inability to communicate well with the investigators (i.e., language problem, poor mental development or impaired cerebral function). 9. participation in a nce clinical study within the previous 3 months or five half-lives, whichever is longer, or a marketed drug clinical study within the 30 days or five half-lives, whichever is longer, before the first dose of imp/nimp. (washout period between studies is defined as the period of time elapsed between the last dose of the previous study and the first dose of the next study). 10. donation of 450 ml or more blood within the 3 months before the first dose of imp/nimp. 11. vegans, vegetarians or other dietary restrictions (e.g., restrictions for medical, religious or cultural reasons, etc.), which would prevent participants from consuming a high-fat breakfast or standardised meal. 12. users of nicotine products i.e., current smokers or ex-smokers who have smoked within the 6 months prior to screening or users of cigarette replacements (i.e., e-cigarettes, nicotine patches or gums). 13. participants who have received a covid-19 vaccine injection within 28 days prior to the first dose of imp/nimp.